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HMG-CoA reductase inhibitors (statins) are effective in lowering of LDL-cholesterol with clinically relevant beneficial effects in the prevention of cardiovascular events (1, 2) . Muscle toxicity is one of the most common adverse event encountered in patients treated with statins, with up to a quarter of patients affected (3) . Statin-associated muscle toxicity ranges from asymptomatic elevation of creatine kinase (CK) activity to myalgia with or without increased CK activity and finally to rhabdomyolysis (4) , which can be life-threatening (5) .
Several mechanisms leading to myopathy have been proposed, among them dysregulated muscle Ca 2+ homeostasis (6, 7) , proteolysis due to increased atrogin-1 expression (8,9), oxidative stress (10) , decreased skeletal muscle coenzyme Q 10 concentrations (7) and inhibition of complex III of the respiratory chain (11) . Impairment of mitochondrial function triggering apoptosis appears to be a central factor in many of the proposed mechanisms (12) (13) (14) (15) . Moreover, statins have been reported to induce apoptosis in skeletal muscle (10, 13) .
Recently, we showed in humans and in rats that statins can trigger apoptosis in fast glycolytic skeletal muscle, and that this mechanism is ROS dependent (13) . In comparison, oxidative skeletal muscle, which has a high mitochondrial content, was not affected by statins. This is in agreement with experiments in L 6 myoblasts, where stimulation of mitochondrial hormesis through PGC-1β was partially protective against the harmful effects of statins (14) . Glycolytic muscle appears to be more sensitive to statins than oxidative muscle, and a high mitochondrial content appears to be protective.
Interestingly, long-term treatment with statins has been reported to decrease mitochondrial content in skeletal muscle, underscoring mitochondrial toxicity of statins (16) (17) (18) . The members of the peroxisome proliferator-activated receptor γ co-activator 1 family (PGC-1)
are considered as key regulators of mitochondrial biogenesis, content and function (19) (20) (21) .
Our previous data showed that statins can protect mitochondria in the highly oxidative cardiac muscle by triggering mitochondrial hormesis via stimulation of PGC-1β expression in both humans and rats (22) . On the other hand, in glycolytic skeletal muscle, we observed a repression of mitochondrial proliferation by statins correlated to impaired expression of PGC-1α and PGC-1β. This mechanism, termed mitochondrial hormesis, proposes that low concentrations of mitochondrial ROS can trigger mitochondrial biogenesis and thereby counteract oxidative stress and re-establish homeostasis (23) (24) (25) (26) .
These observations suggested a role of PGC-1β in statin-associated muscle pathology.
While regulation and function of PGC-1α in skeletal muscle is well established (27) , the role of PGC-1β is currently less clear and debated in the literature (28) (29) (30) . Recently, we described a mouse model with a selective ablation of PGC-1β in skeletal muscle fibers at adulthood (PGC-1β (i)skm-/-mice) (31) , and showed that PGC-1β not only coordinates the expression of genes controlling mitochondrial structure and oxidative phosphorylation, but also genes involved in antioxidative defense such as mitochondrial superoxide dismutase 2 (SOD2).
Since statins are associated with mitochondrial damage including impairment of oxidative phosphorylation and mitochondrial proliferation as well as increased mitochondrial ROS production, we speculated that myotoxicity of statins could be increased in PGC-1β
(i)skm-/-compared to wild-type mice, suggesting a preventive role of PGC-1β in statin-associated myotoxicity. Our current study provides evidence that not only antioxidative capacity and mitochondrial content are important factors for the protection from statin-associated myotoxicity, but also the ability to trigger mitochondrial adaptive pathways such as mitochondrial proliferation, which is at least partially dependent on the function of PGC-1β.
Results
In wild-type and PGC-1β (i)skm-/-mice, atorvastatin treatment impaired skeletal muscle function.
To confirm the efficiency of the treatment, we first analyzed the plasma atorvastatin concentration by LC-MS/MS ( Figure 1A ). As no differences in the plasma atorvastatin concentration were observed between WT-ATO and KO-ATO groups (data not shown), we pooled the values of these two groups. The plasma concentration reached a mean of 20 nM (range 9 nM to 33 nM) in statin-treated animals, which is comparable to what is observed in patient plasma (32) and is in the range of the IC 50 for the inhibition of HMG-CoA reductase (33) . In the plasma of control groups (WT-CTL and KO-CTL), atorvastatin was not detectable (data not shown). Plasma creatine kinase activity reflects muscle damage and can be used as a biomarker for the detection of drug-induced myopathies. Atorvastatin treatment increased the plasma creatine kinase activity in both WT and KO mice (two-way ANOVA treatment main effect p=0.0008, F=17.65), reaching statistical significance for KO-ATO compared to KO-CTL mice ( Figure 1B ). This finding suggested the existence of atorvastatinassociated muscular alterations, particularly in PGC-1β (i)skm-/-mice. To confirm this on a functional level, we performed grip strength tests, and observed that statin treatment decreased mice peak force in both groups compared to their respective control group (twoway ANOVA treatment main effect p=0.0027, F=10.25) ( Figure 1C ). No differences were found in the body weight at the end of the protocol in any group ( Figure 1D ), suggesting that the decrease in muscle strength was associated with muscle dysfunction and not with a general effect on the animals.
Atorvastatin treatment induced a switch from oxidative to glycolytic muscle fiber phenotype.
To get a better insight into the suspected muscular alterations, we performed a hematoxylin and eosin staining on sections of two metabolically different hindlimb muscles: the superficial gastrocnemius, which is mostly glycolytic, and the vastus intermedius, which is mostly oxidative. We observed a decrease of fiber area in the glycolytic muscle ( Figure S1A ) of both WT-ATO and KO-ATO mice compared to their respective control group (two-way ANOVA treatment main effect p=0.0027, F=10.25). Interestingly, atorvastatin decreased the fiber area also in the oxidative muscle of KO mice, but not of WT mice (two-way ANOVA interaction effect p=0.0009, F=21.51) ( Figure S1B ).
To obtain a better insight of the relation between fiber type and statin toxicity, we determined myosin heavy chain isoform (MHC) I, IIA, IIX, and IIB expression in both muscle types. In the glycolytic gastrocnemius muscle, both groups of mice treated with statins exhibited a switch from IIA myofibers, (two-way ANOVA treatment main effect p=0.0002, F=37.10) which are characterized by mitochondrial abundance and oxidative metabolism (34) , and IIAX Taken together, these results suggested that the switch from the oxidative to the glycolytic phenotype potentially could increase the susceptibility of oxidative fibers to atorvastatin.
Since statins are known to impair mitochondrial function in glycolytic skeletal muscle (13, 22) , it was of interest to study mitochondrial function and mitochondrial adaptations in PGC-
Atorvastatin impaired mitochondrial function in glycolytic muscle of wild type and PGC-1β (i)skm-/-mice whereas oxidative muscle exhibited defects only in PGC-1β ablated mice.
In agreement with previous results obtained in the glycolytic tibialis anterior muscle (31) , histochemical staining revealed decreased activity of mitochondrial complex I (NADH dehydrogenase) in the superficial gastrocnemius of PGC-1β (i)skm-/-mice (two-way ANOVA genotype main effect p<0.0001, F=73.64) ( Figure 3A) . Moreover, treatment with atorvastatin was associated with a decrease of NADH dehydrogenase staining of the gastrocnemius muscle of WT and KO mice compared to their respective control group (two-way ANOVA treatment main effect p<0.0001, F=166.13), leading to additive effects of these two parameters (two-way ANOVA interaction effect p=0.0027, F=13.66) ( Figure 3A ). The percentage of stained fibers was also decreased in the oxidative vastus intermedius muscle of KO-ATO mice compared to KO-CTL, but not in the WT-ATO mice (two-way ANOVA interaction effect p=0.0033, F=14.72) ( Figure 3B ). We observed no difference in NADH dehydrogenase staining between control groups in the oxidative muscle.
Based on these results, we determined the mitochondrial respiration rates in permeabilized fibers from both muscle types. Atorvastatin treatment for two weeks impaired the glycolytic muscle mitochondrial function in both WT and KO mice ( Figure 4A ). Although no differences were found in the basal respiratory rates, atorvastatin treatment decreased OXPHOS C I - 
but not in the respective control mice. In comparison, no significant differences were found in the Respiratory Control Ratio (RCR) of the gastrocnemius ( Figure 4B ). In the oxidative soleus muscle, mitochondrial function was impaired by atorvastatin only in KO mice ( Figure   4C Figure 4D ).
If the above-mentioned hypothesis were correct, the observed impairment in mitochondrial function should be associated with increased mitochondrial H 2 O 2 production, especially under reverse electron flux conditions. Mitochondrial H 2 O 2 production was increased in the glycolytic gastrocnemius muscle, in both WT-ATO and KO-ATO groups (two-way ANOVA treatment main effect p=0.0006, F=15.17) compared to their respective control group under reverse electron flux conditions ( Figure 4E ). In the oxidative soleus, H 2 O 2 production was also increased in KO-ATO compared to KO-CTL mice ( Figure 4F ). These measurements enabled us to calculate the Free Radical Leak (FRL), which was increased in the atorvastatin-treated groups (two-way ANOVA treatment main effect p=0.0016, F=11.88, DF=1), especially in the KO-ATO group compared to KO-CTL in the glycolytic muscle ( Figure   4G ). Although the cellular reduced glutathione (GSH) pool, an important constituent of the antioxidative defense system, was affected in the gastrocnemius in the PGC-1β Mitochondrial adaptive pathways were involved for statin tolerance.
To determine the consequences of oxidative stress, we then investigated the mitochondrial biogenesis pathway in more detail. In the glycolytic gastrocnemius muscle, we observed an impairment of the mitochondrial biogenesis pathway in WT-ATO compared to WT-CTL mice with a significant decrease of PGC-1α and PGC-1β mRNA levels, whereas the decrease in the mRNA levels of NRF1, TFAm and NRF2 was not statistically significant ( Figure 5A Figure 5C ) and a significant decrease in the mtDNA content in WT-ATO compared to WT-CTL mice ( Figure 5F ). In the gastrocnemius muscle of KO-ATO mice, although we did not observe a decrease in mitochondrial biogenesis-linked proteins, we noticed a decrease in TOMM20 and a trend for a decrease in cytochrome b expression ( Figure 5C ) as well as a decrease in the mtDNA content compared to KO-CTL mice ( Figure 5F ). This was confirmed by the two-way ANOVA results, which revealed a main effect of atorvastatin for TOMM20 (p=0.0030, F=15.21), cytochrome b (p=0.0329, F=6.34), and mtDNA (p=0.0003, F=19.74). In the oxidative vastus intermedius muscle, we observed in WT-ATO an activation of the mitochondrial biogenesis pathway with an increase in PGC-1β compared to WT-CTL mice ( Figure 5D ). This was confirmed with the increase in TOMM20 and cytochrome b expression and in the mtDNA content ( Figure 5F ). In KO-ATO mice, although we did not observe a decrease in mitochondrial biogenesis-linked proteins, we observed a decrease in cytochrome b protein expression ( Figure 5D ), and in the mtDNA content compared to KO-CTL mice ( Figure 5F ). These observations were confirmed by the two-way ANOVA results, which revealed an interaction effect for cytochrome b (p=0.0002, F=34.70), and mtDNA (p=0.0008, F= 15.40).
PGC-1β protected the oxidative muscle from statin-induced apoptosis.
Western blot analysis of caspase 3 ( Figure 6A ) revealed in the glycolytic gastrocnemius an effect of atorvastatin treatment (two-way ANOVA treatment main effect p=0.0001, F=21.01), with a 2-fold increase in the cleaved caspase 3/total caspase 3 ratio in WT-ATO compared to WT-CTL, and a 2.2-fold increase for KO-ATO compared to KO-CTL. In the oxidative muscle, no differences were observed between WT-CTL and WT-ATO, but this ratio was increased We first showed that atorvastatin treatment decreased the grip strength in wild-type and PGC-1β (i)skm-/-mice. This decrease was correlated with an increase of creatine kinase in the ATO-treated mice compared to CTL mice. Although the absence of PGC-1β in PGC-1β
(i)skm-/-mice exacerbated atorvastatin-induced CK release, it was not associated with an increase in the reduction of the muscle peak force, suggesting that atorvastatin itself could cause this toxicity. Our data showed a decreased muscle fiber area in glycolytic muscle from both mice models. These results in the wild-type groups are in line with what has been previously described by us and by others (8, 35) , showing statin-induced muscular atrophy in glycolytic muscle. Hanai et al. described an increased atrogin-1 mRNA expression in patients with statin-induced muscle injury (8) . A similar increase was also observed in C2C12 myoblasts at the mRNA and at the protein level (35) . In addition, Bonifacio et al. showed a decrease in the phosphorylation of FoxO3, which is responsible for the increase in atrogin-1 expression and for the induction of the atrophic phenotype. Interestingly we also detected a decrease of muscle fiber area in oxidative muscle of PGC-1β (i)skm-/-mice. These results could possibly be explained by the fact that PGC-1β has been reported to suppress protein degradation by decreasing FoxO3 transcriptional activity (36) , and that reduced PGC-1β expression is associated with muscle wasting (37).
Contrary to glycolytic skeletal muscle, oxidative skeletal muscle appears to be protected from the harmful effects of statins (13, 38, 39) . Oxidative muscle is mainly composed of type I slowtwitch and type IIA fast-twitch fibers, whereas glycolytic muscle contains mainly type IIB and type IIX slow-twitch fibers (40) . Although overexpression of PGC-1β has been shown to promote the formation of type IIX fibers in skeletal muscle (41) , PGC-1β deficiency did not affect fiber type composition (31) . These data showed that the PGC-1β deficient oxidative vastus intermedius muscle, when exposed to atorvastatin, developed a similar myofiber phenotype as the glycolytic gastrocnemius muscle. To date, the molecular regulation of fibertype determination is not completely understood. Factors proposed to drive the formation of oxidative myofibers include AMP-activated protein kinase (AMPK) and PGC-1α (42,43) but not PGC-1β (31) . On the other hand, glycolytic muscle determination has been described to result from activation of Akt through a mechanism involving Baf60c, a transcriptional cofactor enriched in fast-twitch muscle, and DEP domain-containing mTOR-interacting protein (44) . In our previous study we showed however, that the activation of Akt is impaired by statins in C2C12 cells mainly due to a reduced mTORC2 activity (9) . The observed shift from type IIA to type IIB fibers in PGC-1β (i)skm-/-mice treated with atorvastatin may therefore involve different mechanisms than activation of Akt.
We observed an impaired mitochondrial function in glycolytic and oxidative muscles of KO mice, but only in glycolytic muscle in WT. Mitochondria appear to adapt better to the toxic stress associated with statins in skeletal muscle with an oxidative phenotype than with a glycolytic one. Maximal OXPHOS respiratory rate depends on convergent electron flow through complexes I & II to the Q-junction of the electron transport chain (45) . Biosynthesis of CoQ 10 is dependent on mevalonate production within the cell. Statins potentially decrease the biosynthesis of ubiquinone by inhibiting mevalonate production. This decrease in ubiquinone formation could therefore be a plausible explanation for the decrease in mitochondrial oxygen consumption. In the current study, the serum atorvastatin concentrations were not different between WT-ATO and KO-ATO mice, suggesting also similar concentrations in skeletal muscle and similar effects on ubiquinone biosynthesis.
Since we observed impaired function of the electron transport chain only in skeletal muscle with a glycolytic, but not with an oxidative phenotype, we considered a decrease in the skeletal muscle ubiquinone content an unlikely explanation for mitochondrial dysfunction. In support of this assumption, in rats with muscle damage due to treatment with increasing doses of cerivastatin, the skeletal muscle ubiquinone content was not different from vehicletreated control rats (46) . In addition, the data regarding the effect of CoQ 10 supplementation in patients with statin-associated myopathy are inconsistent (47) . It appears that the skeletal muscle CoQ 10 content remains high enough in most patients treated with statins to maintain the electron transport chain function. Interestingly, it has recently been reported that statininduced myopathy is associated with a direct inhibition of mitochondrial complex III at the Q 0 ubiquinone site level (11) , which is known to be a site of mitochondrial ROS generation (48).
In addition, if the Q 0 ubiquinone binding site at complex III is impaired, complex II delivers a higher quantity of electrons to ubiquinone than complex III can accept, leading to an "over- in triggering antioxidative defense and mitochondrial proliferation in oxidative muscle in the presence of a mitochondrial toxicant such as atorvastatin. We previously showed that statins had opposite effects on mitochondria of cardiac and skeletal muscle (22) . Indeed, we observed that statins had deleterious effects on skeletal muscle and beneficial effects on the cardiac muscle by triggering the mitochondrial hormesis phenomenon. In a more recent publication, we showed that statins can trigger mitochondrial apoptotic pathways in glycolytic skeletal muscle, whereas oxidative skeletal muscle was resistant (13) . Moreover, we recently showed in vitro that increasing the mitochondrial content by triggering mitochondrial hormesis could protect L 6 myoblasts from the deleterious effects of statins (14) .
In the present study, we confirm that the mitochondrial content is an important factor in preventing statin-associated toxicity. Indeed, statins seem to have beneficial effects not only in the heart, but also in skeletal muscles displaying an oxidative metabolism with a high mitochondrial content. On the other hand, in glycolytic muscles which possess a lower mitochondrial content, statins trigger apoptotic pathways in a mitochondrial ROS-dependent manner. In addition, we show the importance of the ability to adapt the mitochondrial biogenesis pathways to counteract statin-associated toxicity in a long-term setting.
Mitochondrial function and adaptation capacities could hence partially explain why some patients are developing a statin-induced myopathy, and some are tolerant to statins. These data underscore the importance of mitochondrial biogenesis for statin tolerance, and define a hinge role of PGC-1β in mitochondrial adaptation to oxidative stress.
Methods

Animals
Experiments were performed on adult mice (18-23 weeks at the beginning of the study; ~30-35g). Generation of PGC-1β (i)skm-/-mice, in which PGC-1β is selectively ablated in skeletal muscle myofibers at adulthood, has been described previously (31) . Briefly, PGC-1β 
Sample collection
Animals were killed by cervical dislocation and tissues were immediately collected, weighed, and a part of each muscle tissue was immediately frozen in isopentane cooled by liquid nitrogen and stored at -80°C for later analysis, or processed for biochemical and histological analysis. The oxidative soleus muscle and the glycolytic superficial part of the gastrocnemius muscle were excised and cleaned of adipose and connective tissues. We conducted our experiments on different muscles, separating them by muscle type. Muscles are classified by mitochondrial mass: we used the superficial part of the gastrocnemius muscle, which is mostly glycolytic, with a low mitochondrial content. For the oxidative-type muscles with a high mitochondrial content, we studied the soleus muscle, and the vastus intermedius: the most oxidative part of the quadriceps, which is located close to the femur bone.
Plasma biochemistry
Blood was collected by cardiac puncture immediately after death in ethylenediaminetetracetic acid (EDTA)-rinsed tubes and then centrifuged at 1100 g for 15 min at 4°C. The plasma was separated and stored at -80°C until analysis. The analysis of plasma biochemical parameters was performed on randomly selected plasma samples. Plasmatic creatine kinase activity was determined using the Creatine Kinase Activity Assay Kit from Sigma-Aldrich (MAK116; St Louis, USA), according to the manufacturer's instructions.
Atorvastatin plasma concentrations
Atorvastatin was analyzed on an UHPLC system (Shimadzu, Kyoto, Japan) connected to an API 5500 tandem mass spectrometer (AB Sciex, Ontario, Canada). The UHPLC system 
Grip strength Test
A Grip Strength Meter (Bioseb, Vitrolles, France) was used to measure combined forelimb and hindlimb grip strength. The test was repeated three consecutive times within the same session, and the mean value was recorded as the maximal grip strength for each mouse. All tests were performed by the same operator.
Histology
The analysis of all histological parameters was performed on randomly selected slides 
Myosin heavy chain expression immunofluorescence
Immunofluorescence analysis of MHC expression was performed as described by (51) 
Study of muscle mitochondrial respiration
This technique ensured determination of global mitochondrial function, reflecting both the density as well as the functional properties of the muscle mitochondria (52). The mitochondrial respiration was studied from saponin-skinned fibers that keeping mitochondria in their architectural environment, in superficial gastrocnemius, and soleus muscles. The analysis took place in a thermostated oxygraphic chamber at 37°C with continuous stirring When OXPHOS C I -linked substrate state was recorded, electron flow went through complexes I, III, and IV The maximal OXPHOS respiration rate C I+II -linked substrate state was then measured by adding succinate (25 mM (53) . Resorufin has excitation and emission wavelengths of 563 nm and 587 nm, respectively, and is extremely stable once formed. Table S1 . Quantification of gene expression was performed by the method described in (54), using the 18S gene as the internal control. The amplification efficiency of each sample was calculated as described by Ramakers et al. (55) .
GSH content
GSH content was determined in superficial gastrocnemius and the oxidative part of quadriceps muscles (10 mg) using the GSH-Glo Glutathione Assay kit from Promega, following the manufacturer's instructions.
Western blotting
Approximately 20 mg of rat skeletal muscle (superficial gastrocnemius and the oxidative part of the quadriceps) was homogenized with a microdismembrator for 1 min at 2000 rpm Table S1 , as described by (56)). mtDNA content was estimated by calculating the inverse of the CT COX2 /CT Hk2 ratio. Results are expressed as mean ±SEM; n=8-13 per group, *p<0.05, **p<0.01. (i)skm-/-mice, leading to the formation of oxidative stress, the triggering of apoptotic pathways, and a shifting towards highly glycolytic fiber type. Oxidative muscle contains higher antioxidant defences that protect this muscle from the action of statins, leading to cell survival. However, the loss of PGC-1β renders the oxidative muscle susceptible to statins leading to the appearance of oxidative stress and subsequently to apoptosis.
